Rebuilding Microbiome Drug Development to Tackle Translational & Manufacturing Bottlenecks
- Challenge assumptions around clinical endpoints and trial design to improve translational success
- Address cost-of-goods and production scalability to unlock sustainable development pathways
- Reframe the probiotic–drug divide to clarify modality, mechanism, and market potential